HOME > BUSINESS > Mangalam Drugs Vapi plant starts trial operations

Mangalam Drugs Vapi plant starts trial operations

mangalamdrugsMangalam Drugs & Organics said the expansion works of its Plant on Unit-2 situated at Vapi have been successfully completed.

The company commenced the trial operations at this newly expanded plant on 22nd August.

The plant will produce the active pharmaceutical ingredients (API) for Malaria and anti-retroviral drugs.

The Company will be filing Drug Master File (DMF) for all its product with World Health Organization Geneva, it said.

DMFs are used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs to regulatory agencies.

It also plans to file DMF’s of certain API’s with United States Food & Drug Administration in the due course of time.

The total cost of the expansion was approximately Rs 30 Crore which was completed in time.

Mangalam Drugs & Organics Limited commenced in 1977 its manufacturing of Active Pharmaceutical Ingredients APIs, Intermediates at VAPI – Gujarat. It has a multi-product manufacturing facility on two locations, and an in-house R&D.

Follow ULTRA.news
Panacea Biotech, Serum Institute in polio vaccine tie-up Panacea Biotec said it signed two long-term agreements with the world's largest vaccine manufacturer, Serum Institute of India Pvt. Ltd, for manufacturing polio vaccines with a potential market size of $1.25 bln per year. The vaccine will also protect against six other diseas...
Ipca Laboratories acquires US pharma manufacturer for $9.65 mln Ipca Laboratories Ltd said it is has acquired US-based drug manufacturer Pisgah Labs Inc. for US$ 9.65 millions free of debt. The acquisition is aimed at establishing the company's foothold in the US market in the field of contract research and small-volume manufacturing of a...
OrbiMed Asia invests $7.5 mln more in Vivimed Labs unit Vivimed Labs said it will receive $7.5mn investment from OrbiMed Asia into its API business as a follow on to the $42.5 mn invested in September 2017. At the time, Vivimed has said that the proceeds will be utilised for debt reduction at the parent entity level as well as for...
Lupin gets USFDA nod for scalp solution Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd. Calcipotriene Topical Solution is indicated for the topical treatment of chroni...
Sun Pharma’s eye drug application accepted by USFDA Sun Pharmaceutical Industries Ltd said the US FDA has accepted a New Drug Application (NDA) for its OTX-101 dry eye drug. The application will now be processed for approval. Dry eye is a condition in which the eye does not produce tears properly, or when the tears are not of t...
Suven gets neuro drug patents in India, Canada Suven Life Sciences Ltd said it has been granted one patent each in Canada and India for drugs for treating Neurodegenerative diseases. The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028. The chemical entities are consider...
Amara Raja inaugurates new 2-wheeler battery plant Amara Raja Batteries Ltd said it has inaugurated the first phase of its two-wheeler battery plant in Chittoor with a capacity of 5 mln units per year. Before this, the company had a capacity of only 12 mln two-wheeler batteries per year. The new plant will have an ultimate...
Royal Orchid opens 46th hotel in Dwarka, Gujarat Royal Orchid Hotels announced the opening of its new hotel in the pilgrimage town of Dwarka in Gujarat. “We are taking continuous steps towards expanding our presence all over India. The new hotel launch in Dwarka is one such move towards our aim," said Chander K. Baljee, Mana...
TT to set up mega garment plant in UP to move from textiles to garments TT Ltd said it has decided to set up a mega garment plant in place of Spinning Machinery at Gajroula in Uttar Pradesh. The move is part of its attempt to diversify from textile making to making garments. "TT is exiting from spinning and entering the garmenting and fabric b...
Lupin gets US approval for generic version of Bayer’s oral contraceptive Pharma Major Lupin said it got the approval of the US Food and Drug Administration to launch a generic version of Bayer's oral contraceptive Safyral. The branded version has annual sales of around $23 mln in the US. Lupin's product will be called Tydemy. The combination...
Glenmark reports successful trial for nasal spray, to file NDA soon Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its nasal spray Ryaltris met safety and efficacy goals in a Phase 3 clinical study in treating perennial allergic rhinitis. With the positive results, the company said it plans to submit an applica...
Neuland Laboratories acquires Hyderabad factory from Arch Pharma Pharma manufacturer Neuland Laboratories said it acquired a manufacturing plant located near Hyderabad from Arch Pharma Labs Limited. The facility is spread across 12 acres and has a capacity of about 197 KL, the company said. The plant was inspected by the USFDA in 2015, ...
Havells to expand ‘Standard’ brand beyond switches, targets 1,000 cr sales Havells India said it has launched water heaters, switches and MCBs under its Standard Electricals brand, which has been known for its switchgear for close to five decades in India. The company said that it expects to expand sales under Standard to Rs 1000 crore in the next 3...
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash. "We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences. Last month, Strides Shasun said it was sel...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab. "Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim Indian pharma company Biocon and its partner Mylan said EU authorities have accepted for review their applications for approving cancer treating biosimilars trastuzumab and pegfilgrastim submitted after completing corrective actions. The applications were resubmitted last mo...
Dr Reddy’s says EU approves production at Duvvada plant in Andhra Pharma major Dr Reddy's Laboratories said European Union authorities have again allowed it to produce drugs for sale in the EU region at its Duvvada factory in Andhra Pradesh. In its inspection conducted in September, the Regulatory Authority of Germany (Regierun von Oberbayer...
Panacea Biotec gets US nod for generic version of cancer drug Abraxane Panacea Biotec said it got the regulatory nod in the US for launching a generic version of big-selling cancer drug Abraxane. The drug will be sold with the help of Canadian pharmaceutical distributor Apotex. The annual sale of Abraxane worldwide is approximately US$973.4 m...
Dr Reddy’s gets served with class action lawsuit Pharma major Dr Reddy's Laboratories said it has been served with a class action lawsuit, originally announced in August, related to public disclosures made about regulatory action against the company. "Further to our intimation dated August 28, 2017 with regard to US Securit...
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash. "This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...